Top 5 Japanese Stocks To Buy Right Now: Codexis Inc.(CDXS)
Codexis, Inc. engages in the production of custom industrial enzymes for use in the manufacture of biofuels, chemicals, and pharmaceutical ingredients. The company offers Codex Biocatalyst Panels and Kits to pharmaceutical companies that are engaged in drug development and the marketing of approved drugs to allow them to screen and identify possible enzymatic manufacturing processes for their drug candidates and their marketed products. It also provides enzyme screening services, enzyme optimization services, and enzymes, as well as supplies intermediates and active pharmaceutical ingredients to pharmaceutical companies. In addition, the company develops CodeXyme cellulase enzymes to convert cellulosic biomass, a non-food plant material into affordable sugars, which can then be converted into renewable fuels and chemicals; and CodeXol detergent alcohols that are used to manufacture surfactants, which are used as cleaning ingredients in consumer products, such as shampoos, liquid soaps, and laundry detergents. It intends to market CodeXyme cellulase enzymes to chemicals manufacturers; and CodeXol detergent alcohols as a drop-in substitute for the detergent alcohols market. The company has strategic collaborations with Royal Dutch Shell plc and Iogen Energy Corporation for the production of cellulosic ethanol from wheat straw and corn stover feedstocks. Codexis, Inc. was founded in 2002 and is headquartered in Redwood City, California.
Advisors' Opinion:- [By Maxx Chatsko]
The company will now compete more readily with industry leaders Novozymes from Novo Nordisk (NYSE: NVO ) and Genencor from DuPont (NYSE: DD ) . However, the biggest effects could be felt at Codexis (NASDAQ: CDXS ) , which has also licensed the cutting-edge host organism from Dyadic. Will BASF's push into industrial enzymes, specifically using the C1 platform, vindicate Codexis or shove it out of! the way?
source from Top Penny Stocks For 2015:http://www.topstocksforum.com/top-5-japanese-stocks-to-buy-right-now.html
No comments:
Post a Comment